Selank Dosing: Nasal Spray vs Injection

Selank is a synthetic heptapeptide analog of tuftsin, studied mainly in Russian-language animal and small human pilot literature for anxiety-like behavior, stress adaptation, and cognitive effects. It is sold in some markets as an intranasal solution and is also used off-protocol by subcutaneous injection. Neither formulation is FDA-approved for any condition, and Selank is not on the FDA's 503A bulk drug substances list for compounding (FDA 503A bulk list). Full regulatory context is on the FDA status page and the FDA Peptide Status Tracker.

The question people actually want answered is not "what is the dose" but "does the route matter enough to justify the added risk of injection." The honest answer: route affects how much peptide plausibly reaches circulation intact, but no human trial has compared nasal versus injected Selank for any outcome, so any preference for one route is a judgment call, not an evidence-based one.

What doses have actually been reported, and where do they come from?

The published pharmacology of Selank is almost entirely preclinical, using intraperitoneal or intranasal administration in rodents and, in one case, monkeys, to study stress behavior, memory, and neurochemistry (Selank and tuftsin family peptides in stress adaptation, compensatory and antiamnestic effects in monkeys, effects on learning and memory optimization). These studies report doses in micrograms per kilogram of body weight, which does not translate directly to a human milligram dose without allometric assumptions the studies were not designed to support.

One small human clinical report evaluated Selank in generalized anxiety disorder and neurasthenia and describes a treatment course, but this is a single trial-style report from 2008, not a body of confirmatory human dosing evidence, and does not establish a validated dose-response relationship (efficacy and mechanisms in generalized anxiety disorders and neurasthenia).

Outside the published literature, informal user and vendor practice describes intranasal regimens (drops or metered spray, often described as delivering roughly 100 to 900 micrograms per actuation depending on concentration) and subcutaneous injection regimens using reconstituted powder. None of these regimens have been validated in controlled human trials. They are practice patterns, not dosing guidance, and HealthRX.com is not endorsing them by describing them.

Does the route change what you're actually getting?

Intranasal delivery is the route most consistent with the animal literature examining central nervous system effects, since nasal mucosa allows some peptides to bypass first-pass hepatic metabolism and potentially reach the brain via olfactory or trigeminal pathways. But absorption through human nasal mucosa is affected by spray technique, mucosal condition, and formulation, none of which is standardized for Selank products sold outside a regulated supply chain.

Subcutaneous injection bypasses nasal absorption variability entirely and, in theory, delivers a more consistent fraction of the peptide into systemic circulation. In practice, this route depends on sterile reconstitution technique, accurate concentration of the product, and correct storage, and introduces injection-site risk (infection, irritation) that nasal use does not carry. See reconstitution and nasal administration mechanics for the practical detail on preparation, which is a separate question from whether either route is safe or effective for a given person.

Neither absorption theory has been tested against clinical outcomes in a head-to-head human trial. A plausible pharmacokinetic argument for one route being "better" is not the same as evidence that it works better.

What does "as needed" versus scheduled dosing even mean here?

Reports describe both patterns: short courses timed around acute stress exposure, and longer daily courses over several weeks modeled loosely on the anxiety trial protocol. The animal studies on stress and anxiety-like behavior used repeated daily dosing over the study period, not single doses (Selank and Taftsin derivatives in adaptive behavior under stress). Whether an intermittent, as-needed pattern in humans produces any meaningful effect is unverified, since no controlled human trial has tested that dosing pattern against a scheduled one.

Is there a way to make an informed decision without a validated dose?

Selank route and regimen decision map (informational, not a recommendation)

This is a framework for organizing questions to ask, not a clinical dosing protocol. If someone is already using Selank, the decision that matters more than route is whether they have a plan for recognizing an adverse reaction and stopping, discussed in Selank side effects and safety signals.

What would make this decision different?

If a controlled human trial directly compared intranasal and injected Selank on a defined anxiety or cognitive outcome, this page's uncertainty would shrink. That trial does not currently exist in the material available. Until it does, route selection is being made on pharmacological plausibility and practice reports, not confirmed human dose-response data. Anyone weighing this against an FDA-approved anxiolytic, where dosing is established and monitored, should look at that gap directly rather than assume Selank's informal dosing carries comparable certainty; see Selank versus SSRIs and Selank versus benzodiazepines for how the evidence bases compare.

What should prompt stopping and seeking care?

Any signs of allergic reaction (rash, swelling, difficulty breathing), significant injection-site infection (spreading redness, fever, pus), or a new or worsening psychiatric symptom after starting Selank warrant stopping use and contacting a clinician or urgent care rather than adjusting the dose or route. Because Selank is not FDA-approved and has no established human safety monitoring protocol, there is no validated guidance on what dose or route is "safe enough" to continue through mild symptoms.

Evidence boundary

Established: Selank has been studied in animal models across stress, anxiety-like behavior, and memory paradigms using intraperitoneal and intranasal routes, with reported peptide-level and behavioral effects. Plausible but unproven: that intranasal or subcutaneous administration in humans reproduces a similar effect profile, and that any specific reported dose or schedule is optimal or even reliably active. Not established: any validated human dose, any comparative efficacy or safety data between nasal and injected Selank in humans, and any FDA-recognized indication for either route. Readers should treat all reported regimens as informal practice pending controlled human research, and discuss any consideration of Selank with a clinician who can evaluate individual risk.